Advancing Research and Treatment: An Overview of Clinical Trials in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Future Perspectives

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(2), P. 325 - 325

Published: Jan. 6, 2024

Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a chronic, debilitating, and multi-faceted illness. Heterogenous onset clinical presentation with additional comorbidities make it difficult to diagnose, characterize, successfully treat. Current treatment guidelines focus on symptom management, but no clear target or causative mechanism, remission rates are low, fewer than 5% of patients return their pre-morbid activity levels. Therefore, there an urgent need undertake robust trials identify effective treatments. This review synthesizes insights from exploring pharmacological interventions dietary supplements targeting immunological, metabolic, gastrointestinal, neurological, neuroendocrine dysfunction in ME/CFS which require further exploration. Additionally, the trialling alternative based reported efficacy illnesses overlapping symptomology also discussed. Finally, we provide important considerations recommendations, focusing outcome measures, ensure execution future high-quality establish evidence-based that needed for adoption practice.

Language: Английский

---

Potential pharmacological effect of Quercetin Phytosome™ in the management of hyperuricemia: results from real-life clinical studies

Frontiers in Nutrition, Journal Year: 2025, Volume and Issue: 12

Published: Feb. 7, 2025

Hyperuricemia is associated with several metabolic and cardiovascular disorders, traditional treatments, such as xanthine oxidase (XO) inhibitors, often have limitations, severe hypersensitivity reactions or ineffectiveness in achieving target serum urate levels some patients. Quercetin, a naturally occurring flavonoid, has shown potential hypouricemic agent through XO inhibition. This study aims to evaluate the effect of Quercetin Phytosome™ (QP) supplementation across three cohort studies involving healthy adults various health profiles, exploring its safe, effective intervention for hyperuricemia. Clinical data collected clinics Italy between September 2021 April 2024 under real-life clinical settings from distinct studies, were analyzed. Cohort 1 consisted 164 participants (87 QP-treated, 77 probiotic Streptococcus salivarius (S. salivarius) K12-treated) who monitored 90 days. 2 included 22 mildly hyperuricemic disorders receiving QP, while 3 comprised 64 obese hypercholesterolemia, further divided into moderately QP-treated group (n = 20), Berberine monacolins (BM)-treated 22), normouricemic BM-treated 22). QP was administered at 400 mg quercetin daily all cohorts. Primary endpoints reductions uric acid levels, secondary outcomes effects on lipid profile, glycemia, liver enzymes, treatment tolerability. In 1, significantly reduced by 15.2% males 13.8% females, no significant changes observed group. showed 13.1% reduction (p < 0.01) concurrent 10.2% triglycerides 0.05). 3, led 13.7% decrease 20.8% 0.01), well tolerated cohorts, minimal, transient side effects. demonstrates effect. Additionally, triglyceride-lowering benefits evident, particularly metabolically compromised individuals (Cohorts 3), where these statistically significant. With high tolerability, findings highlight Phytosome™'s safe adjunctive therapy hyperuricemia management, meriting investigation larger, randomized trials confirm efficacy safety. clinicaltrials.gov, identifier NCT06652035.

Language: Английский

---

The Impact of Three-Month Quercetin Intake on Quality of Life and Anxiety in Patients With Type II Diabetes Mellitus: An Early Data Analysis From a Randomized Controlled Trial

Cureus, Journal Year: 2024, Volume and Issue: unknown

Published: April 14, 2024

Background: Diabetes is a high-prevalence, major chronic metabolic disease demanding effective interventions. Quercetin, phytochemical with potential health benefits, has garnered interest for its therapeutic properties. Aim: This study was designed to capture the early efficacy and clinical safety aspects following quercetin administration in patients type II diabetes mellitus (T2DM). Methods: The main involved randomized allocation procedure assign non-insulin-treated attending 4th Health Unit of Heraklion intervention control groups based on age sex. group (n=50) received 500 mg daily 12 + (8 free intervals) weeks, alongside their usual treatment, while did not. After randomization, intermediary 12-week follow-up, data from 38 (intervention: 20; control: 18) were analyzed this report. All subjects provided informed consent collection anthropometric measurements, vital signs, habits data, PiKo-6 spirometric readings. Additionally, participants responded Short Anxiety Screening Test (SAST) 36-Item Form Survey (SF-36) questionnaires. Results: Thirty-eight included (60% men 40% women group; 38.9% 61.1% group). In treatment arm, Forced Expiratory Volume first second (FEV1) measured showed Δ%- change arm: +6.8%, -0.2% (p=0.059), systolic blood pressure; intervention: -7.4%, -3.7% (p=0.117), waist circumference; -1.5% -0.7% (p=0.455) night-time sleep; +5.3%, +1.4% (p=0.926) favourably influenced. exhibited significant enhancements both anxiety levels assessed by symptoms scale (SAST-10, p=0.026) quality life evaluated SF-36 (p<0.001). Conclusions: Positive evidence emerging pleiotropic effect intake T2DM, specifically terms reduction amelioration quality, just weeks without adverse effects, indicating underscoring integration T2DM supportive care.

Language: Английский

---

Exploring Therapeutic Potential of Phytoconstituents as a Gut Microbiota Modulator in the Management of Neurological and Psychological Disorders

Neuroscience, Journal Year: 2024, Volume and Issue: 551, P. 69 - 78

Published: May 14, 2024

Language: Английский

---

Quercetin and Its Lecithin-Based Formulation: Potential Applications for Allergic Diseases Based on a Narrative Review

Nutrients, Journal Year: 2025, Volume and Issue: 17(9), P. 1476 - 1476

Published: April 27, 2025

Quercetin, a natural flavonoid, present in various vegetables and fruits, has garnered increasing attraction for its potential antiallergic properties. Its broad-spectrum activity depends on anti-inflammatory, immunomodulatory, antioxidant effects, which target the critical pathways involved type 2-driven allergic inflammation. Quercetin inhibits mast cell degranulation, reduces production of histamine pro-inflammatory cytokines, restores homeostasis immune system by modulating Th1/Th2 Treg/Th17 balances. Additionally, properties help to dampen oxidative stress, factor pathophysiology diseases. In vitro studies have consistently demonstrated quercetin's ability suppress reactions. contrast, vivo studies, particularly murine models rhinitis, confirmed efficacy relieving symptoms (such as nasal itching, sneezing, rhinorrhea, congestion) dampening 2 mucosal Preclinical evidence also supports therapeutic asthma, conjunctivitis, atopic dermatitis, food allergies. However, human are still scarce, only two clinical trials investigated quercetin monotherapy. Both reported promising results, including symptom reduction improved quality life, though larger, randomized needed validate these findings. Some other multicomponent products that contain quercetin. This review aimed report discuss most recent application models. It provides comprehensive overview highlighting an agent supplements manage patients with Moreover, this introduces new phospholipids formulation may represent keystone use. The literature search was based PubMed consultation considering (last five years) publications using keywords "quercetin disease" system".

Language: Английский

---

Benefits of Quercetin on Glycated Hemoglobin, Blood Pressure, PiKo-6 Readings, Night-Time Sleep, Anxiety, and Quality of Life in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(12), P. 3504 - 3504

Published: June 15, 2024

Background: Diabetes is a rapidly growing global morbidity issue with high prevalence, and the associated dysglycemia leads to complications. Patients type 2 diabetes mellitus (T2DM) often experience elevated anxiety levels, affecting their quality of life management. This study investigated quercetin, nutraceutical potential senolytic antioxidant activity, detect its possible positive effect on bio-clinical measurements routine health patients T2DM. Methods: prospective randomized controlled trial (RCT) clinical usefulness quercetin in T2DM receiving non-insulin medications. One hundred participants were stratified by age sex (1:1) control (n = 50) or intervention groups. The received standard care only, while 500 mg daily for 12 weeks, followed an 8-week washout final consecutive 12-week supplementation period (total: 32 weeks), as adjunct usual care. Comprehensive assessments, including blood analyses, conducted at baseline termination. Quality assessed using 36-item Short Form Health Survey (SF-36) Anxiety Screening Test (SAST-10). Results: Eighty-eight concluded trial. Compared control, glycated hemoglobin (HbA1c) levels showed significant decrease (Δ%-change: −4.0% vs. 0.1%, p 0.011). Quercetin also significantly improved PiKo-6 readings (FEV1: 5.6% −1.5%, 0.002), systolic pressure (−5.0% −0.2%, 0.029), night-time sleep (11.6% −7.3%, < 0.001), (SAST-10) (−26.2% 3.3%, (both physical mental components, 0.001). Conclusions: Based current open-label study, appears be promising supplement T2DM, providing lifestyle support. Further research warranted shift this from feasibility multidisciplinary evidence.

Language: Английский

---

Quercetin Phospholipids Supplementation as a Natural Relief in Osteomuscular Health

Physical Medicine and Rehabilitation - International, Journal Year: 2024, Volume and Issue: 11(5)

Published: Dec. 27, 2024

Quercetin, a polyphenol substance, was found in several foods, including apples, grapes, onions, berries, broccoli, citrus fruits, green tea, coffee and red wine. The properties of quercetin are well known, antioxidant/antiinflammatory, vasodilator, anti-allergic, anti-fatigue senolytic. In the present case reports joint health, one month phospholipid supplementation significantly reduced both NRS FIHOA scores erosive hand osteoarthritis subjects. No side effects related to detected, thus would represent valid safe support health pain management as add-on natural support.

Language: Английский

---

Renshen Yangrong decoction for secondary malaise and fatigue: network pharmacology and Mendelian randomization study

Frontiers in Nutrition, Journal Year: 2024, Volume and Issue: 11

Published: June 20, 2024

Background Renshen Yangrong decoction (RSYRD) has been shown therapeutic effects on secondary malaise and fatigue (SMF). However, to date, its bioactive ingredients potential targets remain unclear. Purpose The purpose of this study is assess the RSYRD SMF through a comprehensive strategy integrating network pharmacology, Mendelian randomization as well molecular docking verification. Methods Search for active corresponding protein TCMSP BATMAN-TCM pharmacology analysis. (MR) was performed find SMF. eQTLGen Consortium (sample sizes: 31,684) provided data cis-expression quantitative trait loci (cis-eQTL, exposure). summary (outcome) from genome-wide association studies (GWAS) were gathered MRC-IEU 463,010). We built target interaction between probable ingredient next used drug prediction confirm value targets. Results In RSYRD, investigations revealed 193 possible compounds 234 associated genetically predicted amounts 176 proteins related risk in MR Thirty-seven overlapping treating SMF, among which six (NOS3, GAA, IMPA1, P4HTM, RB1, SLC16A1) prioritized with most convincing evidence. Finally, 14 identified molecules. strong affinity components putative established by docking. Conclusion This several therapy novel insights into feasibility using causal inference Chinese medical formula disease.

Language: Английский

---